Ajinomoto Bio-Pharma  Services emerges from the integration of the businesses and operations of Ajinomoto Althea & Ajinomoto Ajinomoto OmniChem in 2018. As a unified Contract Development and Manufacturing Organization (CDMO), the company's commitment provides its large and small molecule clients accessibility to a broader range of service offerings.

Ajinomoto Bio-Pharma Services includes small molecule manufacturing, formerly OmniChem's Pharmaceutical Custom Manufacturing division (Belgium & India), large molecule manufacturing and aseptic fill finish services, formally Althea (United States) and oligonucleotide manufacturing, formerly GeneDesign (Japan).